TickerGraveyard
TickerGraveyard

AMPE

Bankrupt
Ampio Pharmaceuticals, Inc.

AMPE — Post-Mortem

Ampio Pharmaceuticals, Inc., a Delaware corporation, focused on developing therapies for various medical conditions, notably through its lead candidate, Ampion. Its peak was marked by ambitions surrounding the AP-013 trial results, aiming to demonstrate the efficacy and safety of its treatment for osteoarthritis. However, the company faced a series of legal challenges, including stockholder derivative actions related to its clinical trial results. By January 21, 2025, the District Court in Denver granted preliminary approval for a settlement of these stockholder actions, which stemmed from dissatisfaction with the trial outcomes. Ultimately, despite attempts at resolution, Ampio Pharmaceuticals was dissolved on August 16, 2024, leaving its future contingent on final court decisions, with a

Ampio Pharmaceuticals, Inc. was dissolved on August 16, 2024, following a history of regulatory and financial challenges, culminating in stockholder derivative actions and an eventual settlement.

Could I Have Seen This Coming?

No structured pre-delisting signals found in our records. Absence of signals does not imply absence of risk.

Post-Mortem Analysis

Five-section narrative grounded in primary filings and contemporaneous reporting.

Origin

Ampio Pharmaceuticals was incorporated in Delaware and aimed to innovate in the pharmaceutical industry focused on pain management.

Peak

The company's prominence peaked during attempts to commercialize its primary product, Ampion, with robust clinical studies providing initial investor optimism.

Turning Point

Legal pressures began to mount with multiple stockholder derivative actions over the results of the AP-013 trial, notably impacting investor confidence.

End

On August 16, 2024, the company was officially dissolved, following a court order related to these legal matters and its stated inability to continue operations.

Impact

The dissolution not only marked the end of Ampio's operations but also highlighted ongoing challenges in biotech regarding clinical trial efficacy and stockholder engagement.

Lessons for Today's Investors

Transferable patterns identified from this case, written as research-report observations.

  1. 1

    Investors should monitor legal and regulatory issues closely as they can significantly impair company operations and stockholder value.

  2. 2

    Clinical trials must produce clear and positive outcomes to maintain investor confidence; negative results can lead to extensive legal confrontations.

  3. 3

    Transparency with shareholders regarding trial results and corporate governance is essential for maintaining trust and preventing destructive shareholder actions.

Frequently Asked Questions

What led to the dissolution of Ampio Pharmaceuticals?
The dissolution was a result of significant legal challenges, including stockholder derivative actions related to its clinical trial outcomes, culminating in a court order.
When was Ampio Pharmaceuticals dissolved?
Ampio Pharmaceuticals was dissolved on August 16, 2024.
What was the significance of the January 21, 2025 filing?
The filing indicated the preliminary approval of a proposed settlement for ongoing stockholder derivative actions, reflecting the company’s efforts to resolve its legal issues.

Source Filings

Every fact on this page is anchored to a primary SEC filing or regulatory record. Open any source to verify against the original document.

Narrative sections on this page are AI-assisted summaries of the filings linked above. All content is reviewed against primary sources; if you find an error, the canonical record is always the linked filing.

Categories:

Industries:

Tags:

Related tickers:

Share: